Skip to main content
FARON PHARMACEUTICALS OY logo

FARON PHARMACEUTICALS OY — Investor Relations & Filings

Ticker · FARN ISIN · FI4000153309 LEI · 7437009H31TO1DC0EB42 IL Manufacturing
Open in API
Filings indexed 626 across all filing types
Latest filing 2025-12-08 Regulatory Filings
Country FI Finland
Listing IL FARN

About FARON PHARMACEUTICALS OY

https://faron.com/

Faron Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for cancer. The company pioneers macrophage-targeting therapies to leverage the patient's immune system, aiming to address unmet medical needs and improve outcomes. Its lead asset, bexmarilimab, is a first-in-class anti-Clever-1 antibody and a myeloid cell-targeting immunotherapy candidate. Bexmarilimab is being investigated in clinical trials as a potential therapy for hematological malignancies and solid tumors, often in combination with standard-of-care treatments.

Recent filings

Filing Released Lang Actions
Faron presents updated BEXMAB data at ASH 2025: Deep and durable responses in HR-MDS with favorable safety profile
Regulatory Filings Classification · 98% confidence The document is a press release from Faron Pharmaceuticals announcing updated clinical trial data (BEXMAB study) presented at the ASH 2025 Annual Meeting. It details efficacy, safety, and survival outcomes for a specific drug candidate. While it contains detailed clinical data, it is structured as a corporate press release distributed via a regulatory news service (MFN). It does not constitute a formal financial report (10-K, IR) or a standalone audit report. As it is a general regulatory announcement regarding company activities and clinical progress, it falls under the RNS (Regulatory Filings) category.
2025-12-08 English
Faron Pharmaceuticals Ltd: Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is a 'TR-1: Standard form for notification of major holdings', which is a regulatory requirement for disclosing changes in significant share ownership. It explicitly details the identity of the issuer (Faron Pharmaceuticals Ltd), the person subject to the notification (Timo Syrjälä), and the resulting percentage of voting rights. This aligns perfectly with the definition of a Major Shareholding Notification (MRQ).
2025-12-04 English
Faron Pharmaceuticals Ltd: Registration of New Shares
Share Issue/Capital Change Classification · 100% confidence The document is an official announcement from Faron Pharmaceuticals regarding the registration of 517,795 new shares in the Finnish Trade Register following the exercise of special rights. It details the impact on the total number of shares and voting rights. This falls under the category of share issuance and capital changes.
2025-12-03 English
Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First Tranche Bonds
Share Issue/Capital Change Classification · 100% confidence The document is a company announcement regarding the issuance of new shares resulting from the conversion of bonds (amortisation of First Tranche Bonds). It details the number of shares issued, the subscription price, the impact on total voting rights, and the admission of these shares to trading. This falls under the category of share issuance and capital changes.
2025-12-03 English
Faron Pharmaceuticals Ltd: Grant of Options
Director's Dealing Classification · 100% confidence The document is an official announcement regarding the grant of share options to a person discharging managerial responsibilities (PDMR), specifically Jurriaan Dekkers. It includes the mandatory 'Notification of a Transaction' table required under Article 19(1) of the EU Market Abuse Regulation (MAR). While it involves directors, the specific nature of the disclosure—reporting a transaction in shares/options by a PDMR—is classified under the 'Director's Dealing' category.
2025-12-02 English
Faron Pharmaceuticals Ltd: Appointment of CFO
Board/Management Information Classification · 100% confidence The document is a formal corporate announcement regarding the appointment of a new Chief Financial Officer (CFO) and the retirement of the current CFO at Faron Pharmaceuticals. This falls directly under the category of board or management changes.
2025-12-01 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.